Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment
- PMID: 26008212
- DOI: 10.1007/s00228-015-1862-7
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment
Abstract
Background: The following review is a compilation of the recent advances and knowledge on the behaviour of the most frequently used compounds to treat inflammatory bowel disease in an organism.
Results: It considers clinical aspects of each entity and the pharmacokinetic/pharmacodynamic relationship supported by the use of plasma monitoring, tissue concentrations, and certain aspects derived from pharmacogenetics.
Similar articles
-
Methotrexate for inflammatory bowel disease: time for reconsideration.Expert Rev Gastroenterol Hepatol. 2019 May;13(5):407-409. doi: 10.1080/17474124.2019.1596797. Epub 2019 Mar 21. Expert Rev Gastroenterol Hepatol. 2019. PMID: 30895827 No abstract available.
-
Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.Gastroenterology. 2015 Jun;148(7):1320-9.e3. doi: 10.1053/j.gastro.2015.02.031. Epub 2015 Feb 24. Gastroenterology. 2015. PMID: 25724455 Clinical Trial.
-
Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.Dig Dis Sci. 2018 Jun;63(6):1583-1591. doi: 10.1007/s10620-018-5020-9. Epub 2018 Mar 21. Dig Dis Sci. 2018. PMID: 29564674
-
Golimumab for moderate to severe ulcerative colitis.Expert Rev Gastroenterol Hepatol. 2017 May;11(5):401-406. doi: 10.1080/17474124.2017.1303376. Epub 2017 Mar 9. Expert Rev Gastroenterol Hepatol. 2017. PMID: 28276288 Review.
-
Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary.Gastroenterology. 2019 Jan;156(1):36-42. doi: 10.1053/j.gastro.2018.08.043. Epub 2018 Sep 7. Gastroenterology. 2019. PMID: 30195449 Review.
Cited by
-
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Inflammatory Bowel Disease.Clin Pharmacokinet. 2018 Sep;57(9):1075-1106. doi: 10.1007/s40262-018-0639-4. Clin Pharmacokinet. 2018. PMID: 29512050 Review.
-
Personalized Medicine of Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacogenetics, Therapeutic Drug Monitoring, and Beyond.Front Pharmacol. 2021 Feb 8;11:610806. doi: 10.3389/fphar.2020.610806. eCollection 2020. Front Pharmacol. 2021. PMID: 33628180 Free PMC article. Review.
-
Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease.Int J Clin Pharm. 2020 Apr;42(2):500-507. doi: 10.1007/s11096-020-00978-6. Epub 2020 Jan 31. Int J Clin Pharm. 2020. PMID: 32006141
-
Budesonide-Loaded Hyaluronic Acid Nanoparticles for Targeted Delivery to the Inflamed Intestinal Mucosa in a Rodent Model of Colitis.Biomed Res Int. 2022 Sep 27;2022:7776092. doi: 10.1155/2022/7776092. eCollection 2022. Biomed Res Int. 2022. PMID: 36203483 Free PMC article.
-
Development of An HPLC Method for the Determination of Mesalazine in Human Plasma by Fluorimetric Derivatization and Application to A Prototype Pharmacokinetic Study.J Fluoresc. 2022 Jan;32(1):319-325. doi: 10.1007/s10895-021-02848-4. Epub 2021 Nov 19. J Fluoresc. 2022. PMID: 34797459
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical